liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
University of Helsinki, Finland; Helsinki University Hospital, Finland.
Uppsala University Hospital, Sweden; Uppsala University, Sweden.
Karolinska Institute, Sweden.
CHU Poitiers, France.
Vise andre og tillknytning
2017 (engelsk)Inngår i: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 31, nr 5, s. 1108-1116Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Recent studies suggest that a proportion of chronic myeloid leukemia (CML) patients in deep molecular remission can discontinue the tyrosine kinase inhibitor (TKI) treatment without disease relapse. In this multi-center, prospective clinical trial (EURO-SKI, NCT01596114) we analyzed the function and phenotype of T and NK cells and their relation to successful TKI cessation. Lymphocyte subclasses were measured from 100 imatinib-treated patients at baseline and 1 month after the discontinuation, and functional characterization of NK and T cells was done from 45 patients. The proportion of NK cells was associated with the molecular relapse-free survival as patients with higher than median NK-cell percentage at the time of drug discontinuation had better probability to stay in remission. Similar association was not found with T or B cells or their subsets. In non-relapsing patients the NK-cell phenotype was mature, whereas patients with more naive CD56(bright) NK cells had decreased relapse-free survival. In addition, the TNF-alpha/IFN-gamma cytokine secretion by NK cells correlated with the successful drug discontinuation. Our results highlight the role of NK cells in sustaining remission and strengthen the status of CML as an immunogenic tumor warranting novel clinical trials with immunomodulating agents.

sted, utgiver, år, opplag, sider
NATURE PUBLISHING GROUP , 2017. Vol. 31, nr 5, s. 1108-1116
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-137599DOI: 10.1038/leu.2016.360ISI: 000400464800009PubMedID: 27890936OAI: oai:DiVA.org:liu-137599DiVA, id: diva2:1097371
Merknad

Funding Agencies|Nordic Cancer Union; Finnish Society of Hematology; Biomedicum Helsinki Foundation; Research Foundation of Blood Diseases in Finland; Academy of Finland; Finnish Cancer Organizations; Signe and Ane Gyllenberg Foundation; Finnish Cancer Institute; Doctoral Programme in Clinical Research in the University of Helsinki

Tilgjengelig fra: 2017-05-22 Laget: 2017-05-22 Sist oppdatert: 2018-04-18

Open Access i DiVA

fulltext(1992 kB)91 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 1992 kBChecksum SHA-512
8f6bf43d0b38a5414cb7c62c80e9c8f5266b8b1ce34322eba8f555eed2f400c8fefce3c20186431db1bc31c0d1bb934b6b62016f1c5f0cfa1d97b79aaad98e8a
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Lotfi, Kourosh

Søk i DiVA

Av forfatter/redaktør
Lotfi, KouroshDreimane, Arta
Av organisasjonen
I samme tidsskrift
Leukemia

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 91 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 213 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf